CYCN Cyclerion Therapeutics Inc

USD 3.20 0.12 3.889358
Icon

Cyclerion Therapeutics Inc (CYCN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 3.20

+0.12 (+3.89)%

USD 8.81M

0.02M

N/A

N/A

Icon

CYCN

Cyclerion Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 3.20
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 8.81M

N/A

USD 3.20

Cyclerion Therapeutics Inc (CYCN) Stock Forecast

N/A

Based on the Cyclerion Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Cyclerion Therapeutics Inc is not available over the next 12 months. Cyclerion Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cyclerion Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Cyclerion Therapeutics Inc’s stock price was USD 3.20. Cyclerion Therapeutics Inc’s stock price has changed by +0.00% over the past week, +2.89% over the past month and -64.99% over the last year.

No recent analyst target price found for Cyclerion Therapeutics Inc
No recent average analyst rating found for Cyclerion Therapeutics Inc

Company Overview Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble gua...Read More

https://www.cyclerion.com

245 First Street, Riverview II, Cambridge, MA, United States, 02142

1

December

USD

USA

Adjusted Closing Price for Cyclerion Therapeutics Inc (CYCN)

Loading...

Unadjusted Closing Price for Cyclerion Therapeutics Inc (CYCN)

Loading...

Share Trading Volume for Cyclerion Therapeutics Inc Shares

Loading...

Compare Performance of Cyclerion Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CYCN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Cyclerion Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S +0.35 (+0.27%) USD554.45B 46.01 4.80

ETFs Containing CYCN

Symbol Name CYCN's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Cyclerion Therapeutics Inc (CYCN) Stock

Stock Target Advisor's fundamental analysis for Cyclerion Therapeutics Inc's stock is Bearish.

Unfortunately we do not have enough data on CYCN's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on CYCN's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on CYCN's stock to indicate if its overvalued.

The last closing price of CYCN's stock was USD 3.20.

The most recent market capitalization for CYCN is USD 8.81M.

Unfortunately we do not have enough analyst data on CYCN's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Cyclerion Therapeutics Inc's stock.

As per our most recent records Cyclerion Therapeutics Inc has 1 Employees.

Cyclerion Therapeutics Inc's registered address is 245 First Street, Riverview II, Cambridge, MA, United States, 02142. You can get more information about it from Cyclerion Therapeutics Inc's website at https://www.cyclerion.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...